KELOWNA, BC / ACCESSWIRE / February 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, announces that dosing ...

Lexaria Bioscience (LEXX) announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide rodent biodistribution study. The ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

Where can researchers look for a beacon of hope amid trying times in the pharmaceutical industry? Read on for answers.

target only glucagon-like peptide-1 (GLP-1) and are noted for having muscle loss as a major drawback during weight loss. They show a weight loss effect of about 15 to 20%, but muscle loss can ...

Last month, a production facility dedicated to antibody-drug conjugates ... as various bioactive substances, with glucagon-like peptide (GLP)-1 being a representative example.

Bourla also noted further development expected for Elrexfio (elranatamab), Pfizer’s monoclonal antibody in Phase ... space with its oral glucagon-like peptide-1 receptor agonist (GLP-1RA ...

Bourla also noted further development expected for Elrexfio (elranatamab), Pfizer’s monoclonal antibody in Phase III trialling ... a foray into the metabolic space with its oral glucagon-like ...